spacer
home > pmps > winter 2019 > embracing spray drying strategies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Embracing Spray Drying Strategies

Orally inhaled drug products have several therapeutic advantages over other dosage forms − most notably, a more direct delivery to the central nervous system. By their very nature, they avoid the first pass effect through the liver, for both regional as well as systemic delivery. This allows drug developers to formulate delivery strategies that reduce the dosage strength and limit the risk of adverse side effects. While pharmaceutical companies have long recognised the potential of inhalation products, many are starting to explore development techniques such as spray drying in more depth.

This article will outline the benefits of using respirable-engineered dry powder for inhalation products, as well as discussing how the new 505 (b) (2) application route for faster approval of new formulations that use existing APIs is a suitable pathway to getting these products to market quickly and efficiently.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Aditya R Das PhD, MBA is Director of Business Development at Recipharm and is focussed on inhalation drug product development and commercialisation for global clients. He is responsible for coordinating the interface between client needs and external services and capabilities to facilitate optimal product development and global registration. Aditya has over 25 years’ experience working in combination biopharmaceutical product development, including pulmonary, transdermal, intravenous, implanted, and oral drug delivery therapeutic strategies and is an inventor on eight issued patents. He has a PhD in chemical engineering, an MBA from the University of California, US, an MS degree in chemical engineering from Carnegie Mellon University, US, and a BS degree in chemical engineering from the University of New Hampshire, US.
spacer
Aditya R Das PhD, MBA
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement